News from the EMA: Guidelines announced on bioequivalence for immediate release solid oral dosage forms
News from FDA: CDER Continues to Advance Rare Disease Drug Development with New Efforts, Including the Accelerating Rare Disease Cures (ARC) Program
Reported rates of all-cause serious adverse events following immunization with BNT-162b in 5-17-year-old children in the United States
